Clozapine augmentation: Safety and efficacy

Schizophrenia Bulletin

Volumn 26, Issue 2, 2000, Pages 421-440

  Chong, Siow Ann ^b   Remington, Gary ^a  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b INSTITUTE OF MENTAL HEALTH   (Singapore)

Author keywords

Augmentation; Clozapine; Combination

Indexed keywords

AMOBARBITAL; BENZODIAZEPINE DERIVATIVE; BROMOCRIPTINE; CARBAMAZEPINE; CHLORAL HYDRATE; CLOZAPINE; DEXAMPHETAMINE; LITHIUM; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; ONDANSETRON; RESERPINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID;

ARTICLE; BLOOD TOXICITY; CARDIOTOXICITY; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; ELECTROCONVULSIVE THERAPY; HUMAN; HYPERSALIVATION; LIVER TOXICITY; NAUSEA; NEUROTOXICITY; PRIORITY JOURNAL; SCHIZOIDISM; SCHIZOPHRENIA;

EID: 0033931444     PISSN: 05867614     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.schbul.a033463     Document Type: Article

References (139)

1. Abrams, R. Electroconvulsive Therapy. 2nd ed. New York, NY: Oxford University Press, 1992.
2. Al-Seeman, Y. Bromocriptine as adjunctive therapy to clozapine in treatment-resistant schizophrenia. [Letter]. Canadian Journal of Psychiatry, 41:484-485, 1996.
3. American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia. American Journal of Psychiatry, 154(Suppl 4):1-62, 1997.
4. Andreasen, N.C. The Scale for the Assessment of Negative Symptoms (SANS). Iowa City, IA: The University of Iowa, 1983.
5. Andreasen, N.C. The Scale for the Assessment of Positive Symptoms (SAPS). Iowa City, IA: The University of Iowa, 1984.
6. Armstrong, S.C., and Stephens, J.R. Blood clozapine levels elevated by fluvoxamine: Potential for side effects and lower clozapine dosage. [Letter]. Journal of Clinical Psychiatry, 58:499, 1997.
7. Bak, T.H.; Bauer, M.; Schaub, R.; Hellweg, R.; and Reischies, F. Myoclonus in patients treated with clozapine: A case series. Journal of Clinical Psychiatry, 56:418-422, 1995.
8. Baidessarini, R.J., and Frankenburg, F.R. Clozapine - A novel antipsychotic agent. [Review]. New England Journal of Medicine, 325:51, 1991.
9. Beale, M.D.; Pritchett, J.T.; and Kellner, C.H. Supraventricular tachycardia in a patient receiving ECT, clozapine and caffeine. Convulsive Therapy, 10:228-231, 1994.
10. Beck, A.T. Depression Inventory. Philadelphia, PA: Center for Cognitive Therapy, 1978.
11. Benatov, R.; Sirota, P.; and Megged, S. Neuroleptic-resistant schizophrenia treated with clozapine and ECT. Convulsive Therapy, 12:117-121, 1996.
12. Bender, S.A.; Wolstein, J.R.; Ortmann, K.; Blanke, J.U.; and Paulus, H.J. Treatment of schizophrenia and schizoaffective disorder with a combination of clozapine and lithium. European Neuropsychopharmacology, 6(Suppl 3):200, 1996.
13. Blake, L.M.; Marks, R.C.; and Luchins, D.J. Reversible neurologic symptoms with clozapine and lithium. [Letter]. Journal of Clinical Psychopharmacology, 12:297-299, 1992.
14. Bloch, Y.; Pollack, M.; and Mor, I. Should the administration of ECT during clozapine therapy be contraindicated? [Letter]. British Journal of Psychiatry, 169:253-254, 1996.
15. Bredbacka, P.E.; Paukkala, E.; and Koponen, H. Can severe cardiorespiratory dysregulation induced by clozapine monotherapy be predicted? International Clinical Psychopharmacology, 8:205-206, 1993.
16. Briskin, J.K., and Curtis, J.L. Augmentation of clozapine therapy with ondansetron. [Letter]. American Journal of Psychiatry, 154:1171-1172, 1997.
17. Brunello, N.; Masotto, C.; Steardo, L.; Markstein, R.; and Racagni, G. New insights into the biology of schizophrenia through the mechanism of action of clozapine. Neuropsychopharmacology, 13:177-213, 1995.
18. Buchanan, R.W.; Kirkpatrick, B.; Bryant, N.; Ball, P.; and Breier, A. Fluoxetine augmentation of clozapine treatment in patients with schizophrenia. American Journal of Psychiatry, 153:1625-1627, 1996.
19. Cardwell, B.A., and Nakai, B. Seizure activity in combined clozapine and ECT: A retrospective view. Convulsive Therapy, 11:110-113, 1995.
20. Carpenter, W.T., Jr.; Conley, R.R.; Buchanan, R.W.; Brier, A.; and Tamminga, C.A. Patient response and resource management: Another view of clozapine treatment with schizophrenia. American Journal of Psychiatry, 152:827-832, 1995.
21. Carpenter, W.T., Jr.; Zito, J.M.; Vitrai, J.; and Volavka, J. Hypothesis testing: Is clozapine's superior efficacy dependent on moderate D2 receptor occupancy? Biological Psychiatry, 43:79-83, 1998.
22. Cassady, S.L., and Thaker, G.K. Addition of fluoxetine to clozapine. [Letter]. American Journal of Psychiatry, 149:1274, 1992.
23. Cavallaro, R.; Colombo, C.; and Smeraldi, E. A pilot, open study on the treatment of refractory schizophrenia with risperidone and clozapine. Human Psychopharmacology: Clinical and Experimental, 10:231-234, 1995.
24. Centorrino, F.; Baldessarini, R.J.; Frankenburg, F.R.; Kando, J.; Volpicelli, S.A.; and Flood, J.G. Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors. American Journal of Psychiatry, 153:820-822, 1996.
25. Centorrino, F.; Baldessarini, R.J.; Kando, J.; Frankenburg, F.R.; Kando, J.; Volpicelli, S.A.; Puopolo, P.R.; and Flood, J.G. Serum levels of clozapine and its major metabolite effects of cotherapy with fluoxetine or valproate. American Journal of Psychiatry, 151:123-125, 1994.
26. Chong, S.A.; Tan, C.H.; and Lee, H.S. Hoarding and clozapine-risperidone combination. [Letter]. Canadian Journal of Psychiatry, 41:315-316, 1996.
27. Chong, S.A.; Tan, C.H.; and Lee, H.S. Atrial ectopics with clozapine-risperidone combination. [Letter]. Journal of Clinical Psychopharmacology, 17:130-131, 1997a.
28. Chong, S.A.; Tan, C.H.; and Lee, H.S. Worsening of psychosis with clozapine and selective serotonin reuptake inhibitor combination: Two case reports. [Letter]. Journal of Clinical Psychopharmacology, 17:68-69, 1997b.
29. Cobb, C.D.; Anderson, C.B.; and Siedel, D.R. Possible interaction between clozapine and lorazepam. [Letter]. American Journal of Psychiatry, 148:1601-1602, 1991.
30. Conley, R.R., and Buchanan, R.W. Evaluation of treatment-resistant schizophrenia. Schizophrenia Bulletin, 23(4):663-674, 1997.
31. Costello, L.E., and Suppes, T. A clinically significant interaction between clozapine and valproate. [Letter]. Journal of Clinical Psychopharmacology, 15:139-141, 1995.
32. Coyle, J.T. The glutamate dysfunction hypothesis for schizophrenia. Harvard Review of Psychiatry, 3:241-253, 1996.
33. Dequardo, J.R., and Roberts, M. Elevated clozapine levels after fluoxamine initiation. [Letter]. American Journal of Psychiatry, 153:840-841, 1996.
34. Dickson, R.A.; Williams, R.; and Dalby, J.T. The use of chloral hydrate and sodium amytal during clozapine initiation. Canadian Journal of Psychiatry, 39:132-134, 1994.
35. Dumortier, G.; Lochu, A.; De Mello, P.C.; Ghribi, O.; Rabreau, D.R.; Degrassat, K.; and Desce, J.M. Elevated clozapine concentrations after fluvoxamine initiation. [Letter]. American Journal of Psychiatry, 153:738-739, 1996.
36. Edge, S.C.; Markowitz, J.S.; and Devane, C.L. Clozapine drug-drug interactions: A review of the literature. Human Psychopharmacology: Clinical and Experimental, 12:5-20, 1997.
37. Eggert, A.E.; Crismon, M.L.; and Dolson, P.G. Lack of effect of fluoxetine on clozapine plasma concentrations. [Letter]. Journal of Clinical Psychiatry, 55:454-455, 1994.
38. Endicott, J.; Spitzer, R.L.; Fleiss, J.L.; and Cohen, J. The Global Assessment Scale: A procedure for measuring overall severity of psychiatric disturbance. Archives of General Psychiatry, 33:766-771, 1976.
39. Ereshefsky, L. Pharmacokinetics and drug interactions: Update for new antipsychotics. Journal of Clinical Psychiatry, 57(Suppl 11): 12-25, 1996.
40. Faisal, I.; Lindenmayer, J.P.; Taintor, Z.; and Cancro, R. Clozapine-benzodiazepine interactions. [Letter]. Journal of Clinical Psychiatry, 58:547-548, 1997.
41. Farde, L.; Nordstrom, A.L.; Wiesel, F.A.; Pauli, S.; Halldin, S.; and Sedvall, G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: Relation to extrapyramidal side effects. Archives of General Psychiatry, 49:538-544, 1992.
42. Frances, A.; Docherty, J.P.; and Kahn, D.A. The expert consensus guideline series: Treatment of schizophrenia. Journal of Clinical Psychiatry, 57(12, Pt B):11-50, 1996.
43. Frankenburg, F.R.; Suppes, T.; and McLean, P.E. Combined clozapine and electroconvulsive therapy. Convulsive Therapy, 9:176-180, 1993.
44. Friedman, J.; Ault, K.; and Powchik, P. Pimozide augmentation for the treatment of schizophrenic patients who are partial responders to clozapine. Biological Psychiatry, 42:522-523, 1997.
45. Fuchs, D.C. Clozapine treatment of bipolar disorder in a young adolescent. Journal of the American Academy of Child and Adolescent Psychiatry, 33:1299-1302, 1994.
46. Garcia, G.; Crismon, M.L.; and Dorson, P.G. Seizures in two patients after the addition of lithium to a clozapine regimen. [Letter]. Journal of Clinical Psychopharmacology, 14:426-427, 1994.
47. George, T.P.; Innamorato, L.; Sernyak, M.J.; Baldessarini, R.J.; and Centorrino, F. Leukopenia associated with addition of paroxetine to clozapine. [Letter]. Journal of Clinical Psychiatry, 59:31, 1998.
48. Gerson, S.L.; Lieberman, W.R.; Friedenberg, D.; Lee, D.; Marx, J.; and Meltzer, H. Polypharmacy in fatal clozapine-associated agranulocytosis. [Letter]. Lancet, 338:262-263, 1991.
49. Gerson, S.L., and Meltzer, H. Mechanism of clozapine-induced agranulocytosis. Drug Safety, 7(Suppl 1): 17-25, 1992.
50. Godleski, L.S., and Sernyak, M.J. Agranulocytosis after addition of risperidone to clozapine treatment. [Letter]. American Journal of Psychiatry, 153:735-736, 1996.
51. Goff, D.C., and Baldessarini, R.J. Drug interactions with antipsychotic agents. Journal of Clinical Psychopharmacology, 13:57-67, 1993.
52. Goff, D.C.; Midha, K.K.; Sarid-Segal, O.; Hubbard, J.W.; and Amico, E. A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia. Psychopharmacology, 117:417-423, 1995.
53. Goff, D.C.; Tsai, G.; Manoach, D.S.; Flood, J.; Darby, D.G.; and Coyle, J.T. D-cycloserine added to clozapine for patients with schizophrenia. American Journal of Psychiatry, 153:1628-1630, 1996.
54. Grohmann, R.; Ruther, E.; Sassim, N.; and Schmidt, L.G. Adverse effects of clozapine. Psychopharmacology, 99:S101-S104, 1989.
55. Guy, W., ed. ECDEU Assessment Manual for Psychopharmacology, Revised. (DHEW Publication No. [ADU] 76-338.) Rockville, MD: National Institute of Mental Health.
56. Hamilton, M. A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry, 23:56-62, 1960.
57. Healy, D.J.; Dalack, G.W.; and Meador-Woodruff, J.H. Clozapine-reserpine combination for refractory psychosis. [Letter]. Schizophrenia Research, 25:259-260, 1997.
58. Henderson, D.C., and Goff, D.C. Risperidone as an adjunct to clozapine therapy in chronic schizophrenics. Journal of Clinical Psychiatry, 57:395-397, 1996.
59. Hiemke, C.; Weigmann, H.; Hartter, S.; Dahmen, N.; Wetzel, H.; and Muller, H. Elevated levels of clozapine in serum after addition of fluvoxamine. [Letter]. Journal of Clinical Psychopharmacology, 14:279-281, 1994.
60. Jackson, C.W.; Markowitz, J.S.; and Timothy, D.B. Delirium associated with clozapine and benzodiazepine combinations. Annals of Clinical Psychiatry, 7:139-141, 1995.
61. Jerling, M.; Linstrom, L.; and Bertilsson, L. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: Evidence from a therapeutic drug monitoring service. Therapeutic Drug Monitoring, 16:368-375, 1994.
62. Joffe, G.; Venalaninen, E.; Tupala, J.; Hiltunen, O.; Wahlbeck, K.; Gadeke, R.; and Rimon, R. The effect of clozapine on the course of illness in chronic schizophrenia: Focus on treatment outcome in out-patients. International Clinical Psychopharmacology, 11:265-272, 1996.
63. Johns, C.A., and Thompson, J.W. Adjunctive treatments in schizophrenia: Pharmacotherapies and electroconvulsive therapy. Schizophrenia Bulletin, 21(4):607-619, 1995.
64. Junghan, U.; Albers, M.; and Woggan, B. Increased risk of hematological side-effects in psychiatric patients treated with clozapine and carbamazepine? [Letter]. Pharmacopsychiatry, 26:262, 1993.
65. Kando, J.C.; Tohen, M.; Castillo, J.; and Centorrino, F. Concurrent use of clozapine and valproate in affective and psychotic disorders. Journal of Clinical Psychiatry, 55:255-257, 1994.
66. Kane, J. Clinical efficacy of clozapine in treatment of refractory schizophrenia: An overview. British Journal of Psychiatry, 18(Suppl 17):41-54, 1992.
67. Kane, J.; Honigfeld, G.; Singer, J.; Meltzer, H.; and the Clozaril Collaborative Study Group. Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine. Archives of General Psychiatry, 45:789-796, 1988.
68. Kane, J.M.; Woerner, M.; Borenstein, M.; Weger, J.; and Lieberman, J. Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacology Bulletin, 22:254-258, 1986.
69. Kapur, S., and Remington, G. Serotonin-dopamine interaction and its relevance to schizophrenia. American Journal of Psychiatry, 153:466-476, 1996.
70. 2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: A PET study. Life Science, 57:103-107, 1995.
71. 2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. American Journal of Psychiatry, 156:286-292, 1999.
72. Kay, S.R.; Fiszbein, A.; and Opler, L.A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13(2):261-276, 1987.
73. Kingsbury, S.J., and Puckett, K.M. Effects of fluoxetine on serum clozapine levels. [Letter]. American Journal of Psychiatry, 152:473, 1995.
74. Klapheke, M.M. Clozapine, ECT, and schizoaffective disorder, bipolar type. Convulsive Therapy, 7:36-39, 1991.
75. Klapheke, M.M. Follow-up on clozapine and ECT. [Letter], Convulsive Therapy, 7:303-305, 1991.
76. Klapheke, M.M. Combining ECT and antipsychotic agents: Benefits and risks. Convulsive Therapy, 9:241-255, 1993.
77. Klimke, A., and Klieser, E. Sudden death after intravenous application of lorazepam in a patient treated with clozapine. [Letter]. American Journal of Psychiatry, 151:780, 1994.
78. Koponen, H.J.; Leinonen, E.; and Lepola, U. Fluvoxamine increases the clozapine levels significantly. European Neuropsychopharmacology, 6:69-71, 1996.
79. Koreen, A.R.; Lieberman, J.A.; Kronig, M.; and Cooper, T.M. Cross-tapering clozapine and risperidone. [Letter]. American Journal of Psychiatry, 152:1690, 1995.
80. Koval, M.S.; Rames, L.J.; and Christie, S. Diabetic ketoacidosis associated with clozapine treatment. [Letter]. American Journal of Psychiatry, 151:1520-1521, 1994.
81. 1C receptor antagonists. European Journal of Pharmacology, 245:179-182, 1993.
82. Lacey, R.L.; Preskorn, S.H.; and Jerkovich, G.S. Is risperidone a substitute for clozapine for patients who do not respond to neuroleptics? [Letter]. American Journal of Psychiatry, 152:1401, 1995.
83. Landy, D.A. Combined use of clozapine and electroconvulsive therapy. Convulsive Therapy, 7:218-221, 1991.
84. Lehman, A.F., and Steinwachs, D.M. Translating research into practice: The Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophrenia Bulletin, 24(1):1-10, 1998.
85. Lehmann, H.E., and Ban, T.A. The history of the psychopharmacology of schizophrenia. Canadian Journal of Psychiatry, 42:152-163, 1997.
86. Lemus, C.; Lieberman, J.; and Johns, C. Myoclonus during treatment with clozapine and lithium: The role of serotonin. Hillside Journal of Clinical Psychiatry, 11:127-130, 1990.
87. Lieberman, J.A., and Alvir, J. Report of clozapine induced agranulocytosis in the United States, incidence and risk factors. Drug Safety, 7(Suppl 1):1-2, 1992.
88. Lieberman, J.A.; Kane, J.M.; and Johns, C.A. Clozapine: Guidelines for clinical management. Journal of Clinical Psychiatry, 50:329-338, 1989.
89. Longo, L.P., and Salzman, C. Valproic acid effects on serum concentrations of clozapine and norclozapine. [Letter]. American Journal of Psychiatry, 152:650, 1995.
90. Lurie, S.N. Combined use of ECT and clozapine. [Letter]. Journal of Clinical Psychiatry, 57:94-95, 1996.
91. Markowitz, J.S.; Gill, H.S.; Lavia, M.; Brewerton, T.D.; and DeVane, C.L. Fluvoxamine-clozapine dose-dependent interaction. [Letter]. Canadian Journal of Psychiatry, 41:670-671, 1996.
92. Masiar, S.J., and Johns, C.A. ECT following clozapine. [Letter]. British Journal of Psychiatry, 158:135-136, 1991.
93. McCarthy, R.H., and Terkelsen, K.G. Risperidone augmentation of clozapine. Pharmacopsychiatry, 28:61-63, 1995.
94. Meltzer, H.Y. Clozapine and ECT. [Reply]. Archives of General Psychiatry, 47:219, 1990.
95. Meltzer, H.Y. Treatment of the neuroleptic-nonresponsive schizophrenic patient. Schizophrenia Bulletin, 18(3):515-542, 1992.
96. Miller, D.D. The clinical use of clozapine plasma concentrations in the management of treatment-refractory schizophrenia. Annals of Clinical Psychiatry, 8:99-109, 1996.
97. Mowerman, S., and Siris, S.G. Adjunctive loxapine in a clozapine-resistant cohort of schizophrenic patients. Annals of Clinical Psychiatry, 8:193-197, 1996.
98. Muller, T.; Becker, T.; and Fritze, J. Neuroleptic malignant syndrome after clozapine plus carbamazepine. [Letter]. Lancet, 2:1500, 1988.
99. Naber, D.; Holzbach, R.; Perro, C.; and Hippus, H. Clinical management of clozapine patients in relation to efficacy and side effects. British Journal of Psychiatry, 160(Suppl 17):54-59, 1992.
100. 2 receptor occupancy in relation to clozapine serum concentration: A PET study of schizophrenic patients. American Journal of Psychiatry, 152:1444-1449, 1995.
101. Nordstrom, A.L.; Farde, L.; Weisel, F.A.; Forslund, K.; Pauli, S.; Halldin, C.; and Uppfeldt, G. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: A double-blind PET study of schizophrenic patients. Biological Psychiatry, 33:227-235, 1993.
102. Olney, J.W., and Nuri, N.B. Glutamate receptor dysfunction and schizophrenia. Archives of General Psychiatry, 52:998-1007, 1995.
103. Overall, J.E., and Gorham, D.R. The Brief Psychiatric Rating Scale. Psychological Reports, 10:799-812, 1962.
104. Peacock, L., and Gerlach, J. Clozapine treatment in Denmark: Concomitant psychotropic medication and haematologic monitoring in system with liberal usage practices. Journal of Clinical Psychiatry, 55:44-49, 1994.
105. Perkins, D.O., and Lieberman, J.A. Medical complications and selectivity of therapeutic response to atypical antipsychotic drugs. American Journal of Psychiatry, 155:272-276, 1998.
106. Peterson, G.A., and Byrd, S.L. Diabetic ketoacidosis from clozapine and lithium cotreatment. [Letter]. American Journal of Psychiatry, 153:737-738, 1996.
107. Pope, H.G.; Cole, J.O.; Choas, P.T.; and Fulwiler, C.E. Apparent neuroleptic malignant syndrome with clozapine and lithium. Journal of Nervous and Mental Disease, 174:493-495, 1986.
108. Potkin, S.G.; Jin, Y.; Bunney, B.; Gulasekaram, B.; Costa, J.; Keator, D.B.; Telfor, J.; Wu, J.C.; Najafi, A.; and Bunney, W.E. Clinical and brain imaging effects of adjunctive high dose glycine with clozapine in schizophrenia. Schizophrenia Research, 24:187-188, 1997.
109. Potter, W.Z.; Ko, G.N.; Zhang, L.D.; and Yan, W. Clozapine in China: A review and preview of US/PRC collaboration. Psychopharmacology, 99:S87-S97, 1989.
110. Povlsen, U.J.; Noring, U.; Fog, R.; and Gerlach, J. Tolerability and therapeutic effect of clozapine. Acta Psychiatrica Scandinavica, 71:176-185, 1985.
111. Privitera, M.R.; Lamberti, J.S.; and Maharaj, K. Clozapine in a bipolar depressed patient. [Letter]. American Journal of Psychiatry, 150:986, 1993.
112. Purdon, S.E., and Snaterse, M. Selective serotonin reuptake inhibitor modulation of clozapine effects on cognition in schizophrenia. [Letter]. Canadian Journal of Psychiatry, 43:84-85, 1998.
113. Puri, B.K.; Taylor, D.G.; and Alcock, M.E. Low-dose maintenance clozapine treatment in the prophylaxis of bipolar affective disorder. British Journal of Clinical Practice, 49:333-334, 1995.
114. Raitasuo, V.; Lehtovaara, R.; and Huttunen, M.O. Carbamazepine and plasma levels of clozapine. [Letter]. American Journal of Psychiatry, 150:169, 1993.
115. Rames, L.J., and Christie, S. Diabetic ketoacidosis with clozapine treatment. [Letter]. American Journal of Psychiatry, 151:1520-1521, 1994.
116. Rittmannsberger, H., and Leblhuber, F. Asterixis induced by carbamazepine therapy. Biological Psychiatry, 32:364-368, 1992.
117. Sachdev, P.; Kruk, J.; Kneebone, M.; and Kasse, D. Clozapine-induced neuroleptic malignant syndrome review and report of new cases. Journal of Clinical Psychopharmacology, 15:365-371, 1995.
118. Safferman, A.Z., and Munne, R. Combining clozapine with ECT. Convulsive Therapy, 8:141-143, 1992.
119. Sassim, N., and Grohmann, R. Adverse drug reaction with clozapine and simultaneous application of benzodiazepines. Pharmacopsychiatry, 21:306-307, 1988.
120. Shiloh, R.; Zemishlany, Z.; Aizenberg, D.; Radwan, M.; Schwartz, B.; Dorfman-Etrog, P.; Modai, I.; Khaikin, M.; and Weizman, A. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. British Journal of Psychiatry, 171:569-573, 1997.
121. Silver, H.; Kaplan, A.; and Jahjah, N. Fluvoxamine augmentation for clozapine-resistant schizophrenia. [Letter]. American Journal of Psychiatry, 152:1098, 1995.
122. Silver, H.; Kushnir, M.; and Kaplan, A. Fluvoxamine augmentation in clozapine-resistant schizophrenia: An open pilot study. Biological Psychiatry, 40:671-674, 1996.
123. Simpson, G.M., and Cooper, T.A. Clozapine plasma levels and convulsions. American Journal of Psychiatry, 135:99-100, 1978.
124. Smith, R.C.; Chua, J.W.; Lipetsker, B.; and Bhattacharyya, A. Efficacy of risperidone in reducing positive and negative symptoms in medication-refractory schizophrenia: An open prospective study. Journal of Clinical Psychiatry, 57:460-466, 1996.
125. Smith, T., and Riskin, J. Effect of clozapine on plasma nortriptyline concentration. Pharmacopsychiatry, 27:41-42, 1994.
126. Still, D.J.; Dorson, P.G.; Crimon, M.L.; and Pousson, C. Effects of switching inpatients with treatment-resistant schizophrenia from clozapine to risperidone. Psychiatric Services, 47:1382-1384, 1996.
127. Stoll, A.L.; Pope, H.G.; and McElroy, S.L. High-dose fluoxetine: Safety and efficacy in 27 cases. [Letter]. Journal of Clinical Psychopharmacology, 11:225-226, 1991.
128. Suppes, T.; Philips, K.A.; and Judd, C.R. Clozapine treatment of nonpsychotic rapid cycling bipolar disorder: A report of three cases. Biological Psychiatry, 36:338-340, 1994.
129. Suppes, T., and Rush, A.J. Medication optimization during clozapine treatment. [Letter]. Journal of Clinical Psychiatry, 57:307-308, 1996.
130. Szegedi, A.; Wiesner, J.; and Heimke, C. Improved efficacy and fewer side effects under clozapine therapy after addition of fluvoxamine. [Letter]. Journal of Clinical Psychopharmacology, 15:141-143, 1995.
131. Taylor, D. Pharmacokinetic interactions involving clozapine. British Journal of Psychiatry, 10:9-12, 1997.
132. Taylor, D.; Ellison, L.; Ementon, S.; Wickham, H.; and Murray, R. Co-administration of citalopram and clozapine: Effect on plasma clozapine levels. International Clinical Psychopharmacology, 13:19-21, 1998.
133. Tyson, S.C.; Devane, C.L.; and Risch, S.C. Pharmacokinetic interaction between risperidone and clozapine. [Letter]. American Journal of Psychiatry, 152:1401-1402, 1995.
134. Valevski, A.; Modai, I.; Lahav, M.; and Weizman, A. Clozapine-lithium combined treatment and agranulocytosis. International Clinical Psychopharmacology, 8:63-65, 1993.
135. Venning, G.R. Validity of anecdotal reports of suspected adverse drug reactions: The problem of false alarms. British Medical Journal (Clin Res Ed), 284:249-252, 1982.
136. Wetzel, H.; Anghelescu, I.; Szegedi, A.; Wiesner, J.; Weigmann, H.; Hartter, S.; and Heimke, C. Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: Differential effects of fluvoxamine and paroxetine in a prospective study. Journal of Clinical Psychopharmacology, 18:2-9, 1998.
137. Wilson, W. Do anticonvulsants hinder clozapine treatment? Biological Psychiatry, 37:132-133, 1995.
138. Wirshing, W.C.; Ames, D.; Bisheff, S.; Pierre, J.M.; Mendoza, A.; and Sun, A. Hepatic encephalopathy associated with combined clozapine and divalproex. [Letter]. Journal of Clinical Psychopharmacology 17:120-121, 1997.
139. Zarate, C.A.; Tohen, M.; and Baldessarini, R.J. Clozapine in severe mood disorders. Journal of Clinical Psychiatry, 56:411-417, 1995.